David Nierengarten
Stock Analyst at Wedbush
(3.48)
# 771
Out of 4,814 analysts
219
Total ratings
37.08%
Success rate
6.07%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $15.56 | +73.52% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $20.21 | +68.23% | 3 | Apr 16, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $593.60 | +20.45% | 19 | Apr 16, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $128 | $84.69 | +51.14% | 4 | Apr 16, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $1.92 | +474.41% | 3 | Mar 27, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $7.92 | +316.93% | 6 | Mar 20, 2025 | |
| STRO Sutro Biopharma | Downgrades: Neutral | $8 → $2 | $0.53 | +278.57% | 7 | Mar 14, 2025 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $5 | $1.12 | +346.43% | 15 | Mar 6, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $31 | $12.13 | +155.67% | 2 | Feb 12, 2025 | |
| SWTX SpringWorks Therapeutics | Reiterates: Outperform | $77 | $37.89 | +103.22% | 6 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $20.58 | +94.36% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $33.05 | +172.36% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $30.73 | +52.95% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.55 | -29.82% | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 | $7.27 | +92.70% | 8 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $2.02 | +147.52% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.92 | +1,522.67% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $71.73 | +60.32% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $4.69 | +390.41% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $4.77 | +319.73% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $9.20 | +334.78% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $12.65 | +255.73% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.44 | +594.44% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.23 | +708.99% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $42.24 | +34.94% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.39 | +1,178.45% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.98 | +0.40% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.12 | +78.57% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $4.34 | +130.41% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.65 | +1,592.31% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $9.69 | +271.52% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.24 | +871.66% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $16.25 | +250.77% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $34 | $4.15 | +709.64% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.35 | +1,874.06% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.86 | +17,382.52% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $6.45 | +411.63% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.06 | +1,086.94% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $5.10 | +272.55% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $35.64 | +110.44% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.42 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.16 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.20 | - | 3 | Nov 20, 2017 |
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $15.56
Upside: +73.52%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $20.21
Upside: +68.23%
argenx SE
Apr 16, 2025
Reiterates: Outperform
Price Target: $715
Current: $593.60
Upside: +20.45%
Blueprint Medicines
Apr 16, 2025
Reiterates: Outperform
Price Target: $128
Current: $84.69
Upside: +51.14%
Perspective Therapeutics
Mar 27, 2025
Reiterates: Outperform
Price Target: $11
Current: $1.92
Upside: +474.41%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $7.92
Upside: +316.93%
Sutro Biopharma
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.53
Upside: +278.57%
Fate Therapeutics
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.12
Upside: +346.43%
Bicara Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $12.13
Upside: +155.67%
SpringWorks Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $37.89
Upside: +103.22%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $20.58
Upside: +94.36%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $33.05
Upside: +172.36%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $30.73
Upside: +52.95%
Nov 18, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.55
Upside: -29.82%
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $7.27
Upside: +92.70%
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.02
Upside: +147.52%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.92
Upside: +1,522.67%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $71.73
Upside: +60.32%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $4.69
Upside: +390.41%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $4.77
Upside: +319.73%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $9.20
Upside: +334.78%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $12.65
Upside: +255.73%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.44
Upside: +594.44%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.23
Upside: +708.99%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $42.24
Upside: +34.94%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.39
Upside: +1,178.45%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.98
Upside: +0.40%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.12
Upside: +78.57%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $4.34
Upside: +130.41%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.65
Upside: +1,592.31%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $9.69
Upside: +271.52%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.24
Upside: +871.66%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $16.25
Upside: +250.77%
Mar 19, 2024
Maintains: Neutral
Price Target: $60 → $34
Current: $4.15
Upside: +709.64%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.35
Upside: +1,874.06%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.86
Upside: +17,382.52%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $6.45
Upside: +411.63%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.06
Upside: +1,086.94%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $5.10
Upside: +272.55%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $35.64
Upside: +110.44%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.16
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.20
Upside: -